|
Post by cybergym66 on Oct 18, 2014 18:16:30 GMT -5
More info....
MKC253 is a Technosphere formulation of GLP-1 (glucagon-like peptide). In initial clinical studies, MKC253 showed a lack of the characteristic adverse events, like nausea and vomiting, that are frequently associated with long-acting GLP-1 analogs. Results from a phase 1 trial support the hypothesis that inhalation of MKC253 may be able to simulate the incretin effect that is lost in patients with Type 2 diabetes.
MKC1106 is MannKind’s active immunotherapy platform, and there are three separate programs. MKC1106-PP, designed to target solid tumors, completed an open label phase 1 clinical trial and objective responses were observed in prostate cancer and renal cell carcinoma. MKC1106-MT, specific for melanoma treatment, also showed objective responses in a Phase 1 clinical trial. MKC1106-NS may be applicable to a range of solid and blood cancers and is positioned for clinical evaluation.
MKC204 is an IRE-1 alpha inhibitor with potential application in the treatment of multiple myeloma. IRE-1 alpha is a protein important in the regulation of the Unfolded Protein Response (UPR) cascade. Additional potential indications for UPR pathway inhibitors include autoimmune diseases, cardiovascular diseases and neurodegenerative disorders.
|
|
|
Post by purge on Oct 18, 2014 18:31:59 GMT -5
What should be coming?
|
|
|
Post by jpg on Oct 18, 2014 18:45:18 GMT -5
This tread leaves me unconvinced that we are dealing with facts...
|
|
|
Post by mannmade on Oct 18, 2014 19:03:20 GMT -5
It is my understanding that Mannkind Corp has shuttered their cancer research and development and licensed their current patents etc in this area to a 3rd party and will not be reactivating the oncology R&D division at the company.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 18, 2014 19:24:38 GMT -5
Don't get cranked up over these links. They are remnants from a header that was transitioned when they switched their jobs page to another provider. They have been on the site for as long as I can remember. As others alluded to, these programs were all but backburnered to push afrezza over the finish line.
Whether some of these (or others) are reincarnated remains to be seen. As MNKD moves towards profitability they will no doubt want to spend their money wisely (inhaled headache/migraine meds?)
|
|